Delcath Systems (NasdaqCM:DCTH) FY Conference Transcript

Delcath Systems (NasdaqCM:DCTH) FY Conference September 10, 2025 11:00 AM ET Company ParticipantsGerard Michel - CEO[Analyst]Good morning, and thanks for joining us to have a conversation with Gerard Michel, CEO of Delcath Systems. Delcath is a commercial-stage oncology company focusing on the treatment of liver cancers, and their lead product, HEPZATO, is a minimally invasive percutaneous perfusion technology to treat primary and secondary tumors of the liver. The HEPZATO KIT was launched in January of 202 ...